Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.62 |
| ▸ | HTR3B | O95264 | 2/20 | 0.62 |
| ▸ | HTR3A | P46098 | 2/20 | 0.62 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.62 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | IDO1 | P14902 | 3/20 | 0.49 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.47 |
| ▸ | PNMT | P11086 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | AGXT | P21549 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL836714 | 0.80 | HTR3E (0.37) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL1067715 | 0.79 | CYP3A4 (0.48) | ALDH1A1KMT2ACTBP2TAAR1CHRM2 | |
| SCHEMBL21156700 | 0.78 | MEN1 (0.65) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL481228 | 0.78 | CYP1A2 (0.43) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL1580473 | 0.78 | TAAR1 (0.49) | ALDH1A1IDO1CTBP2TAAR1HDAC6 | |
| SCHEMBL838275 | 0.78 | TAAR1 (0.44) | MEN1KMT2AIDO1HDAC1TAAR1 | |
| SCHEMBL1622220 | 0.77 | HTR3E (1.00) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL10558869 | 0.77 | HTR3E (0.67) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL641405 | 0.76 | IDO1 (0.44) | MEN1ALDH1A1KMT2AIDO1CTBP2 | |
| SCHEMBL434982 | 0.76 | HDAC8 (0.56) | MEN1ALDH1A1KMT2AIDO1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425513-A1 | OXAZOLE, OXADIAZOLE, AND INDOLE DERIVATIVES FOR THE INHIBITION OF USP28 | CARMOT THERAPEUTICS, INC. | 2024-12-26 | — | — | US | disclosed |
| EP-4419508-A2 | OXAZOLE, OXADIAZOLE, AND INDOLE DERIVATIVES FOR THE INHIBITION OF USP28 | Carmot Therapeutics, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-118302414-A | Oxazole, oxadiazole and indole derivatives useful for inhibiting USP28 | 卡莫特医疗有限公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-2023069721-A2 | OXAZOLE, OXADIAZOLE, AND INDOLE DERIVATIVES FOR THE INHIBITION OF USP28 | CARMOT THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023069721-A2 | OXAZOLE, OXADIAZOLE, AND INDOLE DERIVATIVES FOR THE INHIBITION OF USP28 | CARMOT THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20200140400-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2020-05-07 | — | — | US | disclosed |
| US-10562869-B2 | Oxadiazole compounds | REMYND NV (BE) | 2020-02-18 | — | — | US | disclosed |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2017-03-16 | — | — | US | disclosed |
| EP-2272848-B1 | Xanthine derivatives as selective HM74A agonists | GLAXOSMITHKLINE LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8143264-B2 | Xanthine derivatives as selective HM74A agonists | GLAXOSMITHKLINE LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110257205-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GLAXOSMITHKLINE LLC | 2011-10-20 | — | — | US | disclosed |
| EP-2272848-A1 | Xanthine derivatives as selective HM74A agonists | Glaxosmithkline LLC (US) | 2011-01-12 | — | — | EP | disclosed |
| US-20100227845-A1 | SUBSTITUTED 1,2,4-OXADIAZOLES AND ANALOGS THEREOF AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | WU ZHICAI | 2010-09-09 | — | — | US | disclosed |
| EP-2211619-A1 | SUBSTITUTED 1,2,4-OXADIAZOLES AND ANALOGS THEREOF AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | Merck Sharp & Dohme Corp. (US) | 2010-08-04 | — | — | EP | disclosed |
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-20100168122-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-07-01 | — | — | US | disclosed |
| WO-2009051705-A1 | SUBSTITUTED 1,2,4-OXADIAZOLES AND ANALOGS THEREOF AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| CN-101282976-A | Xanthine derivatives as selective HM74A agonists | SMITHKLINE BEECHAM CORP (US) | 2008-10-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562869-B2 | Oxadiazole compounds | OXA1L, PSEN1, MAPT | HTR3E 2479/4885HTR3B 1467/4885HTR3A 1203/4885 |
| US-20240425513-A1 | OXAZOLE, OXADIAZOLE, AND INDOLE DERIVATIVES FOR THE INHIBITION OF USP28 | USP28, USP25, USP39 | HTR3E 1913/4885HTR3B 2277/4885HTR3A 1048/4885 |
| US-20200140400-A1 | OXADIAZOLE COMPOUNDS | OXA1L, PSEN1, MAPT | HTR3E 2633/4885HTR3B 1534/4885HTR3A 1305/4885 |
| US-20100168122-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GPR84, XDH, GPR88 | HTR3E 569/4885HTR3B 162/4885HTR3A 182/4885 |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | OXA1L, PSEN1, MAPT | HTR3E 2479/4885HTR3B 1467/4885HTR3A 1203/4885 |
| US-20100227845-A1 | SUBSTITUTED 1,2,4-OXADIAZOLES AND ANALOGS THEREOF AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | HTR3E 288/4885HTR3B 163/4885HTR3A 197/4885 |
| US-20110257205-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GPR84, GPR88, XDH | HTR3E 401/4885HTR3B 125/4885HTR3A 155/4885 |
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | XDH, GPR84, GPR88 | HTR3E 745/4885HTR3B 212/4885HTR3A 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.